Has Suiwen He, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,123 in general payments to Suiwen He, MD across 49 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Suiwen He, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Suiwen He, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Suiwen He, MD

Nephrology · Kittanning, PANPI 1407051881

Payments from drug & device makers

$1,123in general payments, 2019–2025

Across 49 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Travere Therapeutics, Inc.$444
AstraZeneca$204
Vifor Pharma, Inc.$165
GSK$97
Fresenius USA Marketing, Inc.$77
Ardelyx, Inc.$59
plus $76 from 4 others

What the payments were for

Food & beverage$1,02391%
Education$1009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Travere Therapeutics, Inc.	30	$444
AstraZeneca	2	$204
Vifor Pharma, Inc.	5	$165
GSK	1	$97
Fresenius USA Marketing, Inc.	4	$77
Ardelyx, Inc.	3	$59
Neurocrine Biosciences, Inc.	1	$23
Amgen	1	$20
OPKO Pharmaceuticals, LLC	1	$17
Johnson & Johnson	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

FARXIGA$104

How this compares

$1,123 in reported general payments places this provider in the 60th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$155,732

Medicare patients

406

Services billed

1,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
FarxigaDapagliflozin Propanediol	119	$112,450
JardianceEmpagliflozin	42	$48,943
VeltassaPatiromer Calcium Sorbitex	37	$35,467
AuryxiaFerric Citrate	13	$22,065
LokelmaSodium Zirconium Cyclosilicate	18	$12,783
Sevelamer Carbonate	38	$3,314
Bumetanide	52	$2,762
Potassium Citrate ErPotassium Citrate	21	$2,391
Calcium Acetate	28	$1,705
Losartan Potassium	110	$1,189
Calcitriol	47	$954
Valsartan	22	$714
Hydralazine Hcl	65	$530
Labetalol Hcl	19	$443
Lisinopril	64	$407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AstraZenecaFarxiga, Lokelma	$204	$125,233137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in Kittanning

Charles BettsKittanning$139K
Katalin SusztakPhiladelphia$4.8M
Debbie Cohen SteinPhiladelphia$2.8M
Nelson KopytAllentown$2.1M
Iris LeePhiladelphia$1.9M
Abdallahsassine GearaPhiladelphia$1.2M
Alexander ChangDanville$1000K
Gaia MuallemPhiladelphia$942K
Chike OkechukwuUpland$875K
Christopher GislerPittsburgh$757K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →